A Study to Investigate Safety of GS-248 and Efficacy on Raynauds' Phenomenon in Systemic Sclerosis

NCT ID: NCT04744207

Last Updated: 2024-08-09

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 94 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-12-29
• Study Completion Date: 2022-06-15

Brief Summary

The primary objective of this study is to determine the safety, and evaluate the efficacy of GS-248 versus placebo on Raynaud's Phenomenon (RP) in subjects with Systemic Sclerosis (SSc).

Detailed Description

The primary objective of this study is to determine the safety, and evaluate the efficacy of GS-248 versus placebo on Raynaud's Phenomenon (RP) in subjects with Systemic Sclerosis (SSc).

This is a randomized, double-blind, placebo-controlled study conducted in multiple sites in 4 countries in Europe. Approximately 80 subjects will be randomized in a 1:1 allocation to receive either GS-248 (120 mg) or placebo once daily. The study will comprise an enrolment period, a treatment period, and a follow-up period, with a total of 5 study visits over approximately 10 weeks.

Conditions

Systemic Sclerosis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

GS-248

GS-248, capsule, 120 mg, once daily for 4 weeks

Group Type: EXPERIMENTAL

GS-248

Intervention Type: DRUG

120 mg, capsule, once daily for 4 weeks

Placebo

placebo, capsule, once daily for 4 weeks

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

capsule, once daily for 4 weeks

Interventions

GS-248

120 mg, capsule, once daily for 4 weeks

Intervention Type: DRUG

Placebo

capsule, once daily for 4 weeks

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Subjects must provide signed and dated written informed consent before the conduct of any study-specific procedures.
• Male and female subjects aged 18-75 years inclusive.
• Systemic Sclerosis diagnosed according to European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) criteria (van den Hoogen F et al. 2013). Subjects with signs of other autoimmune diseases (e.g. Sjögren's syndrome, myositis, rheumatoid arthritis) could be included if SSc is the dominating phenotype.
• Raynaud attacks typically ≥7 times per week during the last 4 weeks prior to screening despite background medication (only allowed vasodilatory therapy is calcium channel blockers or PDE-5 inhibitors).
• Women of childbearing potential must be using a highly effective method of contraception to avoid pregnancy throughout the study and for 4 weeks after the last dose of Investigational Medicinal Product in such manner that the risk of pregnancy is minimised.
• Women must not be pregnant or breastfeeding.
• Male subjects to agree to use condom in combination with use of contraceptive methods with a failure rate of <1% to prevent pregnancy and drug exposure of a partner, and refrain from donating sperm from the first date of dosing until 3 months after last dosing of the IMP.
• Ability of subjects to participate fully in all aspects of this clinical trial.

Exclusion Criteria

• Systemic Sclerosis disease duration of greater than 120 months from first non-Raynaud manifestation
• Current smokers or stopped smoking <3 months prior to Visit 1.
• Dose-change or initiation of vasodilating substances (calcium blockers or PDE-5 inhibitors) within 4 weeks prior to Visit 1.
• Use of iloprost or other intravenous (iv) or po prostacyclin receptor agonist within 4 weeks prior to Visit 1.
• Ongoing treatment with immunosuppressive therapies (other than mycophenolate) including, but not restricted to; cyclophosphamide, azathioprine, methotrexate, or cyclosporine, or use of those medications within 4 weeks of trial entry.
• Use of systemic corticosteroids during 4 weeks before screening and during the course of the study.
• Concurrent serious medical condition, with special attention to cardiovascular conditions, which in the opinion of the Investigator makes the subject not suitable for this study.
• Prolonged QTcF interval defined as a mean QTcF >450 msec.
• Creatinine clearance <50 mL/min (determined by Cockcroft-Gault equation) at Screening.
• Active digital ulcer (DU) within 4 weeks prior to Visit 1.
• Clinically meaningful laboratory abnormalities at Screening (Visit 1), as determined and documented by the Investigator.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Ergomed

INDUSTRY

Sponsor Role: collaborator

Gesynta Pharma AB

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Charlotte Edenius

Role: STUDY_DIRECTOR

Gesynta Pharma

Locations

Investigator site

Ghent, , Belgium

Investigator Site

Nijmegen, , Netherlands

Investigator site

Gdansk, , Poland

Investigator Site

Krakow, , Poland

Investigator site

Lublin, , Poland

Investigator site

Bath, , United Kingdom

Investigator site

Cambridge, , United Kingdom

Investigator Site

Dundee, , United Kingdom

Investigator site

Leeds, , United Kingdom

Investigator Site

Liverpool, , United Kingdom

Investigator Site

London, , United Kingdom

Investigator site

Manchester, , United Kingdom

Countries

Belgium; Netherlands; Poland; United Kingdom

Provided Documents

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

GS-2001

Identifier Type: -

Identifier Source: org_study_id